1-11 of 11
Pallavi Patwardhan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma

Available to Purchase
Clinical Trials & Observations
Surbhi Sidana, Nausheen Ahmed, Othman Salim Akhtar, Ruta Brazauskas, Temitope Oloyede, Matthew Bye, Doris Hansen, Christopher Ferreri, Ciara L. Freeman, Aimaz Afrough, Larry D. Anderson, Jr, Binod Dhakal, Devender Dhanda, Lohith Gowda, Hamza Hashmi, Melanie J. Harrison, Amani Kitali, Heather Landau, Abu-Sayeef Mirza, Pallavi Patwardhan, Muzaffar Qazilbash, Saad Usmani, Krina Patel, Taiga Nishihori, Siddhartha Ganguly, Marcelo C. Pasquini
Journal: Blood
Blood (2025) 146 (2): 167–177.
https://doi.org/10.1182/blood.2024026216
Published: 2025
Includes: Supplemental data
Journal Articles

Clinical Outcomes in Real-World Patients (RW) with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM): A Retrospective Study Using Electronic Health Records from Flatiron Health and COTA Vantage Databases

Free
Hans C. Lee, Sundar Jagannath, Devender Dhanda, Teofilia Acheampong, Pallavi Patwardhan, Thomas S. Marshall, Suvina Amin, Tao Gu, Sikander Ailawadhi
Journal: Blood
Blood (2023) 142 (Supplement 1): 3775.
https://doi.org/10.1182/blood-2023-173661
Published: 2023
Journal Articles

Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Free
Surbhi Sidana, Nausheen Ahmed, Othman S Akhtar, Michael Heim, Ruta Brazauskas, Doris K. Hansen, Christopher Ferreri, Ciara Louise L. Freeman, Aimaz Afrough, Larry D. Anderson, Jr., Binod Dhakal, Devender Dhanda, Lohith Gowda, Hamza Hashmi, Melanie Harrison, Amani Kitali, Sayeef Mirza, Jinalben Patel, Pallavi Patwardhan, Saad Z Usmani, Krina K. Patel, Siddhartha Ganguly, Marcelo Pasquini
Journal: Blood
Blood (2023) 142 (Supplement 1): 1027.
https://doi.org/10.1182/blood-2023-181762
Published: 2023
Journal Articles

Facility-Related Healthcare Resource Utilization (HCRU) for Patients Treated with Idecabtagene Vicleucel (Ide-Cel, bb2121) in a Real-World (RW) Setting: A Single-Center Experience

Free
Lauren C. Peres, Pallavi Patwardhan, David Huggar, Gabriel De Avila, Laura B. Oswald, Ariel F. Grajales-Cruz, Brandon Blue, Julieta Abraham Miranda, Kayla Reid, Hien Liu, Taiga Nishihori, Kenneth H. Shain, Rachid Baz, Melissa Alsina, Omar Castaneda, Frederick L. Locke, Ciara Louise L. Freeman, Simrandeep Tiwana, Afraim Botros, Doris K. Hansen
Journal: Blood
Blood (2023) 142 (Supplement 1): 5081.
https://doi.org/10.1182/blood-2023-173812
Published: 2023
Journal Articles

Healthcare Resource Utilization and Economic Burden of Cytokine Release Syndrome and Neurotoxicity in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Receiving Idecabtagene Vicleucel in Earlier-Line Settings in the KarMMa-3 Clinical Trial

Free
Sikander Ailawadhi, November McGarvey, Ken Imanak, Sana Mirza, Pallavi Patwardhan
Journal: Blood
Blood (2023) 142 (Supplement 1): 3712.
https://doi.org/10.1182/blood-2023-173938
Published: 2023
Journal Articles

A Pro-Inflammatory State and Peak Cytokines Are Associated with Toxicity and Early Responses in Real-World Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

Free
Doris K. Hansen, Lauren C. Peres, Julieta Abraham Miranda, Kayla Reid, Gabriel De Avila, David Huggar, Pallavi Patwardhan, Laura B. Oswald, Ariel F. Grajales-Cruz, Brandon Blue, Hien Liu, Taiga Nishihori, Kenneth Shain, Rachid Baz, Melissa Alsina, Omar Castaneda, Simran K. Tiwana, Afraim Botros, Frederick L. Locke, Ciara Louise L. Freeman
Journal: Blood
Blood (2023) 142 (Supplement 1): 1004.
https://doi.org/10.1182/blood-2023-174506
Published: 2023
Journal Articles

Estimation of Long-Term Post-Infusion Costs of Care for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Following Administration of Idecabtagene Vicleucel (ide-cel, bb2121) in the KarMMa Clinical Trial

Free
November McGarvey, Thomas Carattini, Brian Ung, Timothy B. Campbell, Ken Imanak, Pallavi Patwardhan
Journal: Blood
Blood (2022) 140 (Supplement 1): 10947–10948.
https://doi.org/10.1182/blood-2022-158190
Published: 2022
Journal Articles

Real-World Treatment Patterns, Healthcare Resource Utilization and Associated Costs Among Patients with Chronic Myeloid Leukemia in Later Lines of Therapy

Free
Ehab L. Atallah, MD, Rodrigo Maegawa, MD, Dominick Latremouille-Viau, MSc, Carmine Rossi, PhD, Annie Guerin, MSc, Pallavi Patwardhan, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 8–9.
https://doi.org/10.1182/blood-2020-136074
Published: 2020
Journal Articles

Targeted Literature Review of Patient Reported Outcomes (PROs) in Chronic Myeloid Leukemia (CML) Patients Receiving Second and Later Lines of Treatment

Free
Shiyu Zhang, Rodrigo Maegawa, MD, Savita Nandal, MBBS, MD, Pallavi Patwardhan, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–27.
https://doi.org/10.1182/blood-2020-140402
Published: 2020
Journal Articles

Comparing the Risk of Complications for Second-Line Treatments of Immune Thrombocytopenia in Veterans: A U.S. National Study

Free
Natalia Ruiz-Negron, PharmD, Jacob Crook, MStat, Matthew T. Rondina, MD, Pallavi Patwardhan, PhD, Qayyim Said, PhD, Isha Desai, MPH, Richard Nelson, PhD, Joanne LaFleur, PharmD, MSPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 85.
https://doi.org/10.1182/blood-2019-121894
Published: 2019
Journal Articles

Retrospective EHR Study on Effectiveness of Eltrombopag in Cancer Treatment-Related Thrombocytopenia

Free
Anjali Pawar, MD, Vamsidhar Velcheti, MD, Lincy S. Lal, Lisa Le, Katherine Andrade, Isha Desai, Pallavi Patwardhan, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1100.
https://doi.org/10.1182/blood-2019-124781
Published: 2019